2018 BioPacific Conference (20th Annual Conference of CABS) Agenda

Theme: Innovation, Collaboration and Globalization

San Mateo Marriott, 1770 South Amphlett Blvd, San Mateo, CA 94402

8:00 AM – 8:45 AM REGISTRATION
8:45 AM – 8:50 AM Welcome Remarks
Yan Wang, PhD, President-elect of CABS and 2018 BioPacific Conference Organizing Committee Chair
8:50 AM – 9:00 AM State of the Society
Alex J. Zhang, PhD, MBA, President of CABS
9:00 AM – 9:30 AM Combining Discreet Immune Mechanisms for Cancer Therapy: From Concept to Clinical Evidence
Nils Lonberg, PhD, Senior VP, Oncology Discovery Biology, Bristol-Myers Squibb
9:30 AM – 10:00 AM In-China-for-Global Biologics: The Exciting Story of WuXi Biologics
Chris Chen, PhD, CEO, WuXi Biologics
10:00 AM-10:15 AM – Coffee Break
10:15 AM-10:55 AM CABS K. Fong Award in Life Sciences
Presenter: Kenneth Fong, PhD, Chairman, Kenson Ventures
Awardees: Guoliang Yu, PhD, Executive Chairman, Crown Bioscience; Venture Partner, OrbiMed Venture
Yuling Luo, PhD, Founder, Chairman, and CEO of Alamar Biosciences
10:55 AM – 11:15 AM Fireside Chat:
Moderator: Cheni Kwok, PhD, CLP, Managing Partner & Founder, Linear Dreams
Yiding(Mike)Chen, Founder and CEO, ACROBiosystems
Scott Liu, PhD, President and CEO, Shanghai Henlius Biotech, Inc.
11:15 AM – 11:55 PM IP Considerations, and Cross-border Licensing and Collaboration
This session will cover intellectual property considerations in drug development and licensing deals; the stories of cross-border licensing deals and collaborations in drug and device
development.
Moderator, Janet Xiao, PhD, JD, Partner, Co-chair, Global Life Sciences Group, Morrison & Foerster

Panelist, Li Feng, PhD, Partner, Finnegan

Panelist, Tony Xue, PhD, CEO, Kelun-Biotech BioPharmaceutical

Panelist, Wilson Lee, Director, United States, Sino-Singapore (Chengdu) Innovation Park Development

Panelist, Steven X. Cui, PhD, JD, Owner, TransPac IP

Panelist, Rufus Pichler, JD, Partner, Morrison & Foerster
12:00 PM – 12:45 PM – Lunch Break
12:45 PM – 1:00 PM Celebrating 20 years of CABS’s Excellence
1:00 PM – 1:30 PM Presentation title will be available later
Sylvaine Cases, PhD, Vice President, Oncology Scientific Innovation, Janssen Pharmaceutical Companies of Johnson & Johnson
1:30 PM – 2:00 PM Innovations, Tools, and Animal Models in Drug Development
This session will cover humanized animal model for immune checkpoint inhibitor evaluation; how to design clinical trial based on animal model; the importance of NGS and liquid biopsy in precision medicine and drug development; and affinity selection mass spectrometry as an innovative platform.

Panelist, Brooke Rock, PhD, Principal Scientist, Amgen

Panelist, Qingcong Lin, PhD, CEO, BioCytogen Boston

Panelist, Tao Chen, Co-founder and CEO of Paragon Genomics

Panelist, Xueheng (Shawn) Cheng, PhD, Chief Technology Officer, Viva Biotech

Panelist, Liyu Wu, PhD, Senior Director, US Pharmaceutical Business Development and Project Management, Novogene

2:00 PM – 2:30 PM A world-class breakthrough in blood cancer treatment done by China biotech company Legend Biotech with CART cell therapy
Li Zhu, PhD, Chief Strategy Officer, Nanjing Legend Biotech and GenScript Biotechnology
2:30 PM – 3:00 PM Developing Innovative Therapeutics
This session will cover the program selection for drug development; clinical trial strategies on immune-oncology drug; companion diagnostics for a successful clinical trial.

Panelist, Daniel Pierce, PhD, Senior Director of Translational Medicine, Celgene

Panelist, John Ning, MD, PhD, Clinical Consultant in Clinical Science and Product Development Oncology for Genentech

Panelist, Jingrong Li, PhD, VP of CMC/Manufacturing, CStone (Suzhou) Pharmaceuticals

Panelist, Xiao-Jun Ma, PhD, Chief Scientific Officer, Advanced Cell Diagnostics

Panelist, Nelson Lin, PhD, Director, Global Commercial Development, AbbVie

3:00 PM – 3:15PM – Coffee Break
3:15 PM – 3:45 PM The regulatory affairs after the enforcement of ICH guideline by CFDA and the comparison of regulatory affairs between China and US
Dan Zhang, M.D., MA, MPH, Chairman, Fountain Medical Development (FMD)
3:45 PM – 4:15PM Harnessing potent immune agonist pathways for oncology and beyond
Deborah Charych, PhD, Executive Director, Nektar Therapeutics
4:15 PM – 4:50 PM Panel Discussion: Investment, Acquisition and IPO in Life Sciences.
This session will cover cross-border life science investment, Sanpower’s acquisition of Dendreon for $819.9 million; IPO in Hongkong vs. US.

Moderator, Huijun Zhou, Ph.D., FACMG, Founder and CEO, iDNA

Panelist, Jimmy Zhang, PhD, MBA, Venture Partner, Lilly Asia Ventures

Panelist, Grace Xu, MBA, Chairperson, Dendreon; Senior Vice President, Sanpower Group

Panelist, Angela Rusakova, Master of Economics, Partner, Deloitte & Touche

Panelist, Rajeev Dadoo, PhD, MBA, Partner, SR One

5:00 PM – Conference Adjourned
8:45 AM – 5:00 PM – Conference (Convene room)
8:45 AM – 5:00 PM – Partnering (Synergy 1 room)
8:00 AM – 6:00 PM – Exhibition hall (Inspire room)
5:00 PM – 7:00 PM – Post-conference Reception Sponsored by Diamond Sponsors (Engage room and courtyard)